Meta-analysis of Excision Repair Cross-complementation Group 1 (ERCC1) Association with Response to Platinumbased Chemotherapy in Ovarian Cancer


Recent studies suggested that the ovarian cancers with negative excision repair cross-complementation group1 enzyme (ERCC1) expression have a better response to platinum-based chemotherapy than those with positiveERCC1 expression. The objective of this study was to evaluate whether ERCC1 expression is associated withresponse to platinum-based chemotherapy in ovarian cancers. MEDLINE, PubMed, Web of Science and CNKIdatabases were used for searching studies relating to ERCC1 protein expression and response to platinum-basedchemotherapy in ovarian cancers. Statistical analysis was based on the method for a fixed effects meta-analysis.Pooled odds ratios (ORs) with 95% confidence intervals for ERCC1 protein expression and response to platinumbasedchemotherapy were generated. Publication bias was investigated with Begg’s test. Five studies involving306 patients with ovarian cancer were included. Compared to patients with positive ERCC1 expression, thosewith negative ERCC1 expression had a better response to platinum-based chemotherapy. The pooled OR was5.264 (95% CI: 2.928 – 9.464, P < 0.001) and publication bias was not found (P = 0.904). The result was similarin both in Asians and Caucasians (P < 0.001 and P = 0.028, respectively). ERCC1 protein e